19.27
+1.145(+6.32%)
Currency In USD
| Previous Close | 18.13 |
| Open | 18.66 |
| Day High | 19.63 |
| Day Low | 18.66 |
| 52-Week High | 25.29 |
| 52-Week Low | 5.12 |
| Volume | 1.56M |
| Average Volume | 1.58M |
| Market Cap | 1.71B |
| PE | -4.73 |
| EPS | -4.07 |
| Moving Average 50 Days | 20.11 |
| Moving Average 200 Days | 14.62 |
| Change | 1.15 |
If you invested $1000 in Travere Therapeutics, Inc. (TVTX) 10 years ago, it would be worth $1,305.56 as of March 13, 2025 at a share price of $19.27. Whereas If you bought $1000 worth of Travere Therapeutics, Inc. (TVTX) shares 5 years ago, it would be worth $1,444.53 as of March 13, 2025 at a share price of $19.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Travere Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:30 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferencePres
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Feb 13, 2025 9:30 PM GMT
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets.
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
GlobeNewswire Inc.
Feb 11, 2025 12:01 PM GMT
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause